USFDA concludes GMP inspection at Piramal Pharma’s USA facility

12 Dec 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded general Good Manufacturing Practices (GMP) inspection at Piramal Pharma’s Lexington (Kentucky, USA) facility. The inspection was conducted from December 03, 2025 to December 10, 2025.

At the conclusion of the inspection, the USFDA issued a Form-483, with four observations. These observations are related to enhancement in procedures and will be classified as a VAI (voluntary action indicated). The Company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines. The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Piramal Pharma Share Price

168.10 0.00 (0.00%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×